Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia  by Conte, Michael S. et al.
Suggested objective performance goals and clinical
trial design for evaluating catheter-based
treatment of critical limb ischemia
Michael S. Conte, MD,a Patrick J. Geraghty, MD,b AndrewW. Bradbury, MD,c Nathanael D. Hevelone, MPH,d
Stuart R. Lipsitz, ScD,e Gregory L. Moneta, MD,f Mark R. Nehler, MD,g Richard J. Powell, MD,h and
AntonN. Sidawy,MD,i San Francisco; Calif; St. Louis, Mo; Birmingham,United Kingdom; Boston,Mass; Portland, Ore;
Aurora, Colo; Hanover, NH; andWashington, DC
Objective: To develop a set of suggested objective performance goals (OPG) for evaluating new catheter-based treatments
in critical limb ischemia (CLI), based on evidence from historical controls.
Methods: Randomized, controlled trials of surgical, endovascular, and pharmacologic/biologic treatments for CLI were
reviewed according to specified criteria regarding study population and data quality. Line-item data were obtained for
selected studies from the sponsor/funding agency. A set of specific outcome measures was defined in accordance with the
treatment goals for the CLI population. Risk factors were examined for their influence on key endpoints, and models of
stratification based on specific clinical and anatomic variables developed. Sample size estimates were made for single-arm
trial designs based on comparison to the suggested OPG.
Results: Bypass with autogenous vein was considered the established standard, and data compiled from three individual
randomized, controlled trials (N  838) was analyzed. The primary efficacy endpoint was defined as perioperative
(30-day) death or any major adverse limb event (amputation or major reintervention) occurring within one year. Results
of open surgery controls demonstrated freedom from the primary endpoint in 76.9% (95% confidence interval [CI]
74.0%-79.9%) of patients at one year, with amputation-free survival (AFS) of 76.5% (95% CI 73.7%-79.5). An additional
3% non-inferiority margin was suggested in generating OPG for catheter-based therapies. Defined clinical (age> 80 years
and tissue loss) and anatomic (infra-popliteal anatomy or lack of good quality saphenous vein) risk subgroups provided
significantly different point estimates and OPG threshold values.
Conclusions: For new catheter-based therapies in CLI, OPGs offer a feasible approach for pre-market evaluation using
non-randomized trial designs. Such studies should incorporate risk stratification in design and reporting as theCLIpopulation
is heterogeneous with respect to baseline variables and expected outcomes. Guidelines for CLI trial design to address
consistency in study cohorts, methods of assessment, and endpoint definitions are provided. (J Vasc Surg 2009;50:1462-73.)Critical limb ischemia (CLI) caused by infrainguinal
atherosclerosis is a substantial source of death and disabil-
ity. One year mortality ranges from 10% to 40%, and
without revascularization up to 40% will suffer limb loss
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1462within six months. Rates of major amputation in Western
countries range from 120 to 500 per million per year.1 The
global epidemic of diabetes, coupled with smoking, diet,
and lifestyle trends, insures that the burden of CLI will
continue to grow. Unfortunately, no pharmacologic or
biologic therapy has achieved broad success in reversing
these arterial obstructions, and in the absence of successful
revascularization, both limb loss and early mortality rates
are substantial. Limb dysfunction, pain, ulceration, and
advanced comorbidities render this an extremely vulnerable
population in considering the safety and effectiveness of
new treatments.
The primacy of surgical bypass for relieving leg isch-
emia has recently been challenged by catheter-based revas-
cularization techniques. Endovascular techniques have the
potential to achieve limb salvage with less procedural mor-
bidity and mortality. However, multiple challenges arise
when attempting to critically evaluate the safety and efficacy
of catheter-based devices for treatment of CLI:
- Inclusion and exclusion criteria for CLI treatment trials
have varied, and must be standardized to permit mean-
ingful comparisons between studies. Ischemic foot pain
can be mimicked by other disease processes, and should
therefore be reinforced by hemodynamic evidence of
severely diminished arterial inflow. Tissue loss is a more
definitive sign of impaired perfusion, yet may also com-
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Documentation of absent pedal pulses, and corroborat-
ing noninvasive data, should thus supplement the use of
ulceration as an inclusion criterion for CLI trials.
- Even with clearly defined entry criteria, it is understood
that CLI encompasses a spectrum of disease severity and
comorbidities, and these factors greatly impact proce-
dural risk, limb related outcomes, and patient survival.
Therefore risk stratification is an important aspect of
clinical trial design and outcomes reporting in this area,
to allow investigators to compare results in subgroups
that are most evenly matched. This is especially true for
data from non-randomized studies.
- Controversy exists regarding the most appropriate effi-
cacy endpoints for evaluation of CLI treatments. For
endovascular therapies, this is compounded by the focus
on vessel segment-specific outcomes such as “target le-
sion- or target vessel-reintervention.” Simultaneous,
multilevel endovascular treatment of both stenotic and
occlusive lesions is frequently required to treat CLI.
Patency assessment of multiple treated arterial segments
is cumbersome, and patency or hemodynamic measures
may not bear a direct relationship to other outcomes,
such as limb salvage. The key outcome events for CLI
patients are survival, limb preservation, avoidance of re-
interventions, and quality of life. However, when report-
ing a more global measure, such as amputation-free
survival (AFS), both the frequency and magnitude of
reinterventions needed to achieve that outcome should
be documented for a given treatment strategy. Multiple
events are common and are not captured in typical
Kaplan-Meier analysis.
- Limb revascularization procedures have inherent short-
term risks including mortality; however, they are not
intended to improve survival. Therefore, endpoints that
couple limb-related outcomes and patient survival over
time (eg, AFS) are inherently compromised as measures
of effectiveness for revascularization. Such endpoints will
be greatly influenced by patient selection factors (comor-
bidities and demographics) which are strongly associated
with survival. Both limb-specific and survival-related end-
points must be considered, especially in non-randomized
comparisons.
Randomized, controlled trials (RCTs) provide the best
scientific evidence for medical decision making. They also
constitute the highest standard by which regulatory bodies
such as the U.S. Food and Drug Administration (FDA)
evaluate the entry of new drugs, devices, or other therapeu-
tics into the marketplace. However, such trials pose signif-
icant ethical, economic, and scientific challenges for the
stakeholders – which include industry, physicians, and the
public at large. Furthermore, RCTs can take considerable
time to complete, and rapid paced changes in technology
may reduce the meaningfulness of their findings. Finally,
some new products constitute minor modifications of oth-
ers already available, or may be considered to pose minimal
risk to human health. In recognition of these and otherissues, multiple pathways exist for the regulatory approval
of therapeutics by FDA, including the 510(k) pathway for
Class II devices. For Class III devices, Pre-Market Approval
(PMA) requires a safety and effectiveness evaluation be
performed (21 CFR 860.7). The FDA Modernization Act
of 1997 provided a “least burdensome” mandate for the
FDA in its evaluation of medical devices. Accordingly, FDA
has determined that the use of well documented historical
controls may constitute an alternative to RCTs in specific
circumstances.2 In the cardiovascular arena, heart valve
prostheses are a prominent example of a mature technology
with large population experience.3 In such cases, the anal-
ysis of validated datasets may be used to generate Objective
Performance Criteria (OPC) against which new products
may be compared in single-arm trials. In less mature tech-
nologies, where historical controls are limited in size,
scope, and quality, Objective Performance Goals (OPGs)
may be suggested and developed over time into OPC.
Recently, OPGs have been suggested in the area of femo-
ropopliteal nitinol stents, for example.4,5 The accompany-
ing perspective by Geraghty et al6 summarizes the regula-
tory framework and potential relevance of anOPG standard
for device development in CLI.
Due to the challenges noted related to the state of
existing evidence, OPGs for catheter-based CLI interven-
tion have previously not been available. We propose the use
of risk-adjusted surgical controls to generate OPG/OPC
for endovascular devices seeking pre-market approval for
the treatment of CLI. Recent availability of validated, mul-
ticenter trial datasets of open bypass surgery makes this a
feasible exercise. Our aim is to suggest a set of standardized
measures for the evaluation of proposed CLI devices via
single-armed prospective data collection, thus facilitating a
timely and cost-efficient premarket assessment of such de-
vices. It should be emphasized that well conducted RCTs
remain the standard for evidence-based medical practice,
and OPGs are not to be confused with practice guidelines.
However an absolute requirement for RCT-level evidence
in the CLI population may unduly hinder innovation in an
area where significant unmet clinical needs exist. Sugges-
tions for the design and conduct of such trials are included
in this manuscript. Adoption of a common trial design for
premarket CLI device evaluation will allow physicians to
effectively partner with industry in bringing safe and effec-
tive treatments to bear on this debilitating disease.
METHODS
Review of literature and database compilation
Randomized controlled trials of surgical, endovascular,
biologic, and pharmacologic treatment of CLI from 1990
to 2007 were reviewed. Autologous vein was considered
the preferred conduit for surgical revascularization. Con-
trol arms from gene therapy and medical therapy trials
were sought to examine the natural history of non-
revascularized CLI. Independently adjudicated data with
clinical follow-up to aminimumof one year was sought.We
identified five multicenter RCTs that met our criteria:
JOURNAL OF VASCULAR SURGERY
December 20091464 Conte et alProject of Ex-Vivo vein graft Engineering via Transfection
III (PREVENT III),7 Circulase I and II,8,9 Bypass versus
Angioplasty in Severe Ischemia of the Leg (BASIL),10,11
and The Study to Assess the Safety of Intramuscular Injec-
tion if Hepatocyte Growth Factor Plasmid to Improve
Limb Perfusion in Patients with Critical Limb Ischemia
(HGF-STAT) trials.12,13 Following the establishment of
data sharing agreements between trial investigators/spon-
sors and the Society for Vascular Surgery, de-identified line
item data were compiled in a central database. After con-
sideration of the quality and quantity of available data from
the natural history cohorts, which was limited and highly
selected, it was determined that this group could not be
employed as a meaningful comparator in any of the OPG.
We therefore focused our analysis on the expected out-
comes for open bypass surgery with autogenous vein. Data
sources for the OPG control group are summarized in
Table I.
Definition of critical limb ischemia (CLI) and study
population
CLI is defined as ischemic rest pain or tissue loss,
consistent with Fontaine Stages III-IV and Rutherford
Classes 4-6. Documentation of severely compromised he-
modynamics (ankle 50 mm Hg, toe 30 mm Hg,
TcPO2 30 mm Hg) verified inclusion of patients with
rest pain. For patients with tissue loss, documentation of
severely compromised hemodynamics, absence of pedal
pulses, or both was sought.
We restricted the analysis to infrainguinal disease, and
to open surgical bypass performed with autogenous vein,
considered as the standard of care for CLI. Patients who
received prosthetic grafts or test drugs, in addition to those
with end-stage renal disease (CKD 5), were excluded from
analysis. In all trials, a per-protocol approach was used in
aggregating data; simple randomization to a treatment
group was not sufficient to gain access to the study popu-
lation.
Safety and efficacy measures
Definition of events and composite endpoints. We
defined a set of outcome variables (Table II) as the basis for
our safety and efficacy targets. Death was used in several of
Table I. Dataset sources for the open surgery control
group (N  838)
Dataset
Total
N
N
used Key exclusions
PREVENT III 1404 605 Study drug, ESRD
CIRCULASE 663 85 Study drug, endovascular arm,
non-vein conduit, ESRD
BASIL 452 148 Endovascular arm, non-vein
conduit, ESRD
BASIL, Bypass versus Angioplasty in Severe Ischemia of the Leg; ESRD,
end-stage renal disease; PREVENT III, Project of Ex-Vivo vein graft Engi-
neering via Transfection III.the composite measures as outlined below. Amputationwas defined by major index limb loss at or proximal to
the transtibial level. Major adverse cardiovascular event
(MACE) included myocardial infarction and stroke in ad-
dition to death from any cause.Reintervention was defined
as any repeat vascular procedure in the index limb. We
subdivided reinterventions intomajor andminor categories
to reflect the magnitude of the procedure and its presumed
impact on the patient. Major reinterventions included the
creation of a new surgical bypass graft, the use of throm-
bectomy or thrombolysis (ie, procedures done in the set-
ting of lost primary-assisted patency), or a major surgical
graft revision such as a jump graft or an interposition graft.
Minor reinterventions included endovascular procedures
(PTA, atherectomy, stenting) without thrombectomy/
thrombolysis, and minor surgical revisions (patch angio-
plasty). Based on this subdivision, we defined a major
adverse limb event as the composite of either amputation or
major reintervention. We combined this limb-specific end-
point with perioperative (30 day) mortality, to generate the
primary efficacy endpoint of perioperative death or any
major adverse limb event. The endpoint reintervention or
amputation captured the first vascular event in the limb
while censoring death.
While reintervention and amputation are clinical events
indicative of revascularization failure, the decision to per-
form reintervention is driven by the approach to surveil-
lance and by objective findings of hemodynamic failure.
These events are thus only indirectly linked to the sustained
effectiveness of the original procedure. Differences in crite-
ria for reintervention can greatly influence clinical end-
points while masking important differences in therapeutic
benefit. Conversely, long term hemodynamic success may
not be required in all patients to achieve meaningful clinical
benefit in CLI. In either case, it is considered that some
measure of sustained hemodynamic improvement is intrin-
sically important in the evaluation of limb revascularization
Table II. Endpoint definitions
Outcome Definition
MALE Major Adverse Limb Event: Above ankle
amputation of the index limb or major
reintervention (new bypass graft, jump/
interposition graft revision, or
thrombectomy/thrombolysis).
MALEPOD Perioperative death (30 days), or any MALE
MACE Major Adverse Cardiovascular Event: MI,
stroke or death (any cause).
AMPUTATION Above ankle amputation of the index limb.
AFS Amputation-Free Survival: Above ankle
amputation of the index limb or death
(any cause).
RAO Any reintervention or above ankle
amputation of the index limb.
RAS Any reintervention, above ankle amputation
of the index limb, or stenosis
DEATH Death (any cause).
MI, Myocardial infarction.procedures. For open surgery, vein graft surveillance is well
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RCT designs such as PREVENT III directly influences
both the timing and occurrence of reinterventions, many of
which are prophylactic and designed to maintain long term
secondary graft patency. Unfortunately, there are no accepted
norms for surveillance or reintervention for catheter-based
treatments. In the Appendix (online only), we suggest an
approach for measuring hemodynamic success in CLI trials
of endovascular devices. For the purposes of generating an
OPG incorporating sustained hemodynamic benefit, we
defined stenosis for the open surgery controls based on
ultrasound graft surveillance criteria, which were available
from PREVENT III.14 This resulted in a composite end-
point that incorporated the first occurrence of reinterven-
tion, amputation, or stenosis.
Safety. We considered 30 days as the standard tempo-
ral window for evaluation of post-procedural adverse
events. Key safety measures includedMACE, major adverse
limb event, and amputation.
Efficacy. We considered one year as an appropriate
minimal exposure time for assessing therapeutic efficacy in
CLI. The key efficacy endpoints should reflect the treat-
ment goal of survival with a functional limb. However, the
need for reinterventions and the magnitude of these rein-
terventions have a clear impact on patient quality of life, and
these were considered by the incorporation of reinterven-
tion into several endpoints, and by count of total number of
reinterventions over the year. Of these measures, we con-
sidered perioperative death or any major adverse limb event
to be primary and amputation-free survival (AFS) as the key
secondary endpoint, which together best captured the clin-
ical efficacy of the initial procedure for treatment of CLI.
Hemodynamic success is also a critical and objective mea-
sure of therapeutic gain for any revascularization proce-
dure, and is best reflected in the surgical control data by
reintervention, amputation, or stenosis. Limb salvage and
survival should also be reported independently. Performance
goals for all six efficacy measures (perioperative death or any
major adverse limb event, AFS, reintervention/amputation/
stenosis, reintervention/amputation, amputation, mortal-
ity) were developed.
Risk stratification variables
The CLI population encompasses a broad spectrum of
disease severity, anatomic determinants, and comorbidities
that influence clinical decision making, and therefore pre-
trial risk stratification should be a consideration in study
designs and outcome comparisons. We considered stratifi-
cation of cohorts based on key variables that would be
available at trial entry, and suitable (from an ethical, clinical,
and practical perspective) for defining either stratification,
exclusion, or focused design of a clinical trial. Stratification
of key predictive variables should be incorporated into trial
design and each subgroup powered adequately. It was
assumed that a two-tiered risk cohort approach would be
most practical for design and execution of studies. Model-
ing of outcomes was performed based on the primary and
key secondary efficacy endpoints at one year. Potentialpredictive categorical variables were assessed with Kaplan-
Meier plots and log-rank tests to determine if the risk
classification resulted in statistically meaningful divergence
of outcomes. Continuous predictive variables were origi-
nally assessed with Cox proportional hazards regression
then subsequently reduced to binary variables based on
clinically significant thresholds where appropriate or (in the
case of age) via a series of analyses performed to find a
breakpoint of maximum effect. For this decision, data was
repeatedly resampled and subsets reassessed for maximum
discrimination between primary and key secondary efficacy
endpoints.
Patient-level risk factors. Demographic, comorbid-
ity, and disease severity variables from the individual trial
databases were examined and variables mapped by common
definitions or groupings. Variables selected for analysis
were age, gender, race, diabetes, hypertension, coronary
artery disease, hypercholesterolemia, chronic renal disease
(CKD class), smoking (ever/never), and CLI criterion (rest
pain vs tissue loss). Comparison of the individual study
populations across these key variables is summarized in
Table III. Sensitivity analysis of age data was performed to
define an optimal threshold for a two-tiered model. This
resulted in the selection of 80 years of age as a meaningful
breakpoint. Results demonstrated that the twomost potent
patient-level predictors at one year were age 80 and
presence of tissue loss (TL) at study entry (Table IV). The
combination of these two variables was assessed in a num-
ber of ways, in a univariate fashion as shown in Fig 1, as a
four-level categorical variable, and in a multivariate propor-
tional hazards model (not shown). This resulted in the
designation of patients with both age 80 and TL as a
“Clinical High Risk” subgroup (N  136).
Anatomic level of disease. The results of endovascular
interventions have been closely linked to anatomic burden of
disease using various grading schemes such as the TASC
classification. By contrast, outcomes of lower extremity bypass
with autogenous vein have not demonstrated a clear relation-
ship to arterial anatomy, although various studies have sug-
gested that graft length and outflowmay have influence. Data
available fromPREVENTandBASIL specified the location of
anastomotic sites; anatomic classification based on preopera-
tive angiographic data was not available. Bypass grafts were
categorized based on the level of the distal anastomosis into
one of two groups; infrapopliteal (anastomosis to a tibial or
pedal vessel) or above (anastomosis to popliteal or superficial
femoral artery at any level). Stratified outcomes based on the
anatomic level are shown in Fig 2. Infrapopliteal anatomy was
designated as an “AnatomicHighRisk” subgroup (N505).
Conduit quality/availablility. The most potent fac-
tor influencing the long term outcomes of autogenous vein
bypass is conduit (vein) quality. Specifically, the ability to
complete a graft procedure using a single segment of great
saphenous vein (SSGSV) results in superior expected out-
comes in comparison to grafts comprised of ectopic veins
either as single-segment or spliced constructs.15 Therefore,
the potential advantages of an endovascular approach for an
individual patient may be greatly influenced by the avail-
SIL.
nt).
factor
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determination may not be completely made until the time
of surgery, we rationalized that conduit availability may be
categorized based on clinical evaluation and ultrasound
vein mapping studies in a significant proportion of patients.
We therefore segregated the surgical bypass data based on
graft composition between those composed of a single GSV
segment of diameter 3 mm versus other venous conduits
(Fig 3). The latter group was designated as a “Conduit
High Risk” subgroup (N  163).
Statistical methods and criteria for determination of
suggested OPG
Differences in frequencies of categorical variables be-
tween contributing datasets were assessed with Chi-square
Table III. Covariate distribution (%) among contributing
PREVENT III
Clinical
Age  80 17.9
Male 64.8
AA race# 17.9
Diabetes 62.3
Smoking 75.5
Hypercholesterolemia 46.0
Hypertension 81.0
TL
†
74.1
Age  80  TL 15.4
Anatomic
Infrapopliteal 66.6
Conduit
Poor quality vein* 26.9
*Poor quality vein is defined as use of a non-single segment greater saphenou
from PREVENT III).
†TL indicates Tissue Loss, which includes both ulceration and gangrene.
#AA race indicates African-American vs all other. Race was not coded in BA
Table IV. Univariate analysis of risk factors
Risk factor
Mortality
  P
Clinical
Age  80 71.8 89.0 .0001
Male 85.3 86.4 .7886
AA race 87.8 85.3 .6276
Diabetes 85.7 85.6 .9386
Smoking 85.4 81.9 .7214
Hypercholesterolemia 88.3 84.2 .0560
HTN 86.7 82.5 .1277
TL 84.1 90.3 .0318
Age  80  TL 70.3 88.7 .0001
Anatomic
Infra-popliteal 85.9 85.3 .7818
Conduit
Poor quality vein 86.3 87.7 .5902
AA, African-American; AFS, amputation-free survival; HTN, hypertension;
Percents are Kaplan-Meier survival estimates at one year (freedom from eve
Comparisons are between those with () versus without () the given risktests. Risk stratified subgroups were determined via assess-ment of potential covariates with univariate Kaplan-Meier
plots and log-rank tests.
After review of the pooled dataset, the Working
Group used a consensus approach to develop the sug-
gested OPGs. Given that catheter-based treatments offer
a less invasive approach in comparison to open surgery,
we felt that a non-inferiority comparison was most rele-
vant for the OPG. For the key safety outcomes (MACE,
major adverse limb event, and amputation within 30
days), the upper bound of the 95% confidence interval
(UCL) for the control group defined the maximum
allowable event rate (OPG) for a less invasive treatment
to be considered not inferior. No additional margin was
incorporated for the safety OPG, as open surgery is
considered more invasive with inherently greater proce-
sources
CIRCULASE BASIL P value
17.7 25.7 .0889
78.8 65.5 .0365
9.4 0 .0001
50.6 39.2 .0001
87.1 82.4 .0195
62.4 62.1 .0005
75.3 58.1 .0001
69.4 75.0 .6145
12.9 21.6 .1244
54.1 37.8 .0001
n/a n/a n/a
for graft construction, or minimum diameter less than 3 mm (available only
MALEPOD AFS
 P   P
.0 78.5 .0324 62.9 79.7 .0001
.7 72.4 .8327 74.9 79.6 .1658
.5 74.3 .1641 74.0 76.9 .3810
.2 79.1 .0475 74.7 78.8 .1596
.9 77.0 .7057 76.1 78.1 .5314
.6 77.8 .6020 79.6 75.1 .1245
.5 78.3 .4119 77.2 74.4 .3493
.0 79.5 .1189 72.8 87.0 .0001
.1 78.3 .0344 60.5 79.6 .0001
.0 81.3 .0041 74.4 79.8 .0718
.2 79.0 .0031 76.4 79.3 .2335
E, major adverse limb event; POD, perioperative death; TL, tissue loss.
.trial
s vein
70
76
65
75
76
76
76
76
69
74
69
MALdural morbidity. Therefore, the upper bound of confi-
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must be equal to or less than the safety OPG (Table Va).
Trial design based on these OPG should be primarily
driven by the key CLI efficacy endpoints. Non-inferiority for
the test therapy was defined as having an observed event rate
within 3% (added margin) of the lower confidence limit
(LCL) for the control group. The OPGs were set to include
this additional margin, so that the LCL for observed events in
the test group should meet or exceed each OPG as reported.
The rationale for an additional margin is based on the pre-
sumed trade-off for a less invasive treatment. The 3% level was
selected as an acceptable compromise between reduced clini-
cal efficacy at one year, likely further decreases in long-term
durability, and reasonable sample sizes for trial design.
We maintained the same 3% margin in setting the OPG
for the infrapopliteal anatomy subgroup, which had a robust
control dataset (N  505). However, both the clinical high-
risk and conduit high-risk categories had significantly smaller
study populations reflected by wider confidence intervals. In
addition, conduit quality was felt to be a unique risk factor
affecting bypass graft performance only. Given these consid-
erations, no additional buffer is suggested for the OPG in the
clinical high-risk and conduit high-risk subgroups.
Suggested sample sizes were based on the primary
efficacy endpoint of perioperative death or any major ad-
Fig 1. Primary (Panel A: Peri-operative death or any Major Ad-
verse Limb Event [MALEPOD]) and Key Secondary (Panel B:
Amputation Free Survival [AFS]) endpoints from the surgical
control dataset, dichotomized by clinical risk (high risk defined as
being both age 80 or older and having tissue loss). N  136 for
high risk and 702 for low risk.verse limb event. These sizes were calculated via a onesample survival method assuming an  of 0.05 and 80%
power, an exponential distribution, and an equivalent one-
year event rate to the OPG sample. A 5% loss to follow-up
was assumed, and an additional adjustment was made to
account for mortality falling outside our endpoint defini-
tion (all deaths following the first 30 days).
RESULTS
Data quality and heterogeneity between trials
Line item data was incorporated into a combined open
surgery dataset when all variables of interest could be
ascertained. In some instances, minor covariate availability
varied between trials; for example, race was not available for
all observations in the BASIL trial while conduit quality and
stenosis could only be assessed in PREVENT-III. The
frequencies of clinical visits also differed from study to study
leading to potential variation in determination of loss to
follow-up. For a full comparison of covariate characteristics
between component trials, please see Table III.
Safety outcome and suggested OPGs
Safety outcomes for the open surgery control group are
summarized in Table Va. Overall 30-day MACE was 6.2%
(95% CI 4.7-8.1), major adverse limb events occurred in
6.1% (95% CI 4.6%-7.9%), and major amputation was 1.9%
Fig 2. Primary (Panel A: Peri-operative death or any Major Ad-
verse Limb Event [MALEPOD]) and Key Secondary (Panel B:
Amputation Free Survival [AFS]) endpoints from the surgical
control dataset, dichotomized by anatomic risk (infra-popliteal vs
otherwise). N  505 for infra-popliteal target and 333 for more
proximal vessel.(95% CI 1.1%-3.1%). The OPG are therefore set at 8%, 8%,
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392 patients for an all-comers trial (see below), the maxi-
mum number of observable safety events is shown in the
table. We suggest that all three of these safety endpoints
should be met individually to achieve the OPG for a new
CLI treatment.
Efficacy measures and suggested OPGs
Summary of the one-year outcomes is presented in
Fig 3. Primary (Panel A: Peri-operative death or any Major Ad-
verse Limb Event [MALEPOD]) and Key Secondary (Panel B:
Amputation Free Survival [AFS]) endpoints from the surgical
control dataset, dichotomized by conduit risk (high risk defined by
use of non-single segment great saphenous vein [SSGSV] or vein
diameter  3mm). N  163 for high risk grafts and 442 for low
risk grafts.
Table Va. Summary of safety outcomes for overall CLI
cohort
Outcome
30 day events
(%; 95% CI)
Maximum allowable
events (trial N  392)
Safety
OPG
MACE 6.2% (4.7-8.1) 20 (5.1%, 3.1-7.8%) 8%
● Death 2.7%
● MI 3.1%
● CVA 1.0%
MALE 6.1% (4.6-7.9) 18 (4.6%, 2.7-7.2) 8%
Amputation 1.9% (1.1-3.1) 5 (1.3%, 0.4-3.0) 3%
CVA,Cerebrovascular accident;MACE,major adverse cardiovascular event;
MI, myocardial infarction.
Maximal events calculated based on trial design using sample size of 392 as
calculated from Table Vb. The upper bound of the 95% Confidence Interval
must be  the OPG.Table Vb, and Kaplan-Meier curves are illustrated in Fig-ures 4-7 (online only). For the primary efficacy endpoint of
perioperative death or any major adverse limb event, free-
dom from event in the control surgery group was 76.9%
(95% CI 74.0%-79.9%) at one year. With the 3% non-
inferiority margin subtracted from the LCL, the OPG for
the primary endpoint is set at 71%. If the observed event
rate in the proposed trial population was identical to that
observed in the surgical controls, a sample size of 392
patients would be required to meet the OPG as defined.
AFS for the combined surgical control population was
76.5% (95% confidence interval 73.7%-79.5%) at one year.
Freedom from amputation or any reintervention was 61.3%
(95% CI 58.0%-64.9%). Freedom from amputation, rein-
tervention or stenosis was 46.5% (95% CI 42.3%-51.2%) at
one year. Limb salvage was 88.9% (95% CI 86.7%-91.1%)
and survival was 85.7% (95% CI 83.3%-88.1%). The respec-
tive OPG rates are listed in Table Vb. It is suggested that all
six of these OPG be met by a candidate device/therapy
tested via a single-arm trial design.
Risk stratified outcomes and suggested OPGs for
defined subgroups
Based on the clinical, anatomic, and conduit high-risk
categories defined above, two level stratified trials or exclu-
sive high-risk cohort designs may be considered. Univariate
Kaplan-Meier analysis demonstrated significantly inferior
outcomes in the clinical high-risk group for the primary and
key secondary efficacy endpoints (Figs 1a and 1b), while
anatomic and conduit high-risk subgroups performed sig-
nificantly worse in the primary endpoint (Figs 2a and 3a).
Safety and efficacy outcomes for each of these risk group-
ings are summarized in Tables VI -VIIIa and b. The format
is identical to Table Va and b. The maximal number of
safety events was calculated based on the sample size re-
quired to meet the primary endpoint OPG for the defined
subgroup. All-comer CLI trials should report their out-
comes data stratified by the clinical and anatomic risk
groupings suggested above, to allow for meaningful com-
Table Vb. Summary of efficacy outcomes (one year) for
overall CLI cohort and suggested OPG for each endpoint
Outcome Point (95% CI) Efficacy OPG
MALE  POD 76.9% (74.0-79.9) 71%
AFS 76.5% (73.7-79.5) 71%
RAS 46.5% (42.3-51.2) 39%
RAO 61.3% (58.0-64.9) 55%
Limb salvage 88.9% (86.7-91.1) 84%
Survival 85.7% (83.3-88.1) 80%
AFS, Amputation-free survival; CI, confidence interval; CLI, critical limb
ischemia; MALE, major adverse limb event; OPG, objective performance
goals; POD, perioperative death; RAO, any reintervention or above ankle
amputation of the index limb; RAS, any reintervention, above ankle ampu-
tation of the index limb, or stenosis.
Rates reported as proportion free from adverse event.parisons to existing datasets.
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Reintervention rate is reported as mean number of
repeat vascular procedures over time in Table IX. These
values are adjusted for the time a particular index limb
remained at risk. This data is provided as a framework for
comparison but is not suggested as an OPG standard at this
time.
DISCUSSION
New and less-invasive therapies are needed to meet the
Table VIa. Summary of safety outcomes for clinical high
risk (age  80 and tissue loss) subgroup
Outcome
30 day events
(%; 95% CI)
Maximum allowable
events (Trial N  264)
Safety
OPG
MACE 11.8% (6.9-18.4) 36 (13.6%, 9.7-18.4) 18%
● Death 6.6%
● MI 5.2%
● CVA 2.2%
MALE 5.1% (2.1-10.3) 17 (6.4%, 3.8-10.1) 10%
Amputation 2.9% (0.8-7.4) 11 (4.2%, 2.1-7.3) 7%
CLI, Critical limb ischemia; CVA, cerebrovascular accident; MACE,
major adverse cardiovascular event; MI, myocardial infarction; OPG,
objective performance goals.
Table VIb. Summary of efficacy outcomes (one year) for
clinical high risk (age  80 and tissue loss) subgroup and
suggested OPG
Outcome Point (95% CI) Efficacy OPG
MALEPOD 69.1% (61.3-78.0) 61%
AFS 60.5% (52.7-69.4) 53%
RAS 40.4% (29.3-55.8) 29%
RAO 62.8% (54.3-72.6) 54%
Limb salvage 86.5% (80.2-93.2) 80%
Survival 70.3% (63.0-78.5) 63%
AFS, Amputation-free survival; CI, confidence interval; MALE, major ad-
verse limb event; OPG, objective performance goals; POD, perioperative
death; RAO, any reintervention or above ankle amputation of the index
limb;RAS, any reintervention, above ankle amputation of the index limb, or
stenosis.
Rates reported as proportion free from adverse event.
Table VIIa. Summary of safety outcomes for anatomic
high risk (infra-popliteal) subgroup
Outcome
30 day events
(%; 95% CI)
Maximum allowable
events (Trial N  317)
Safety
OPG
MACE 7.3% (5.2-10.0) 21 (6.6%, 4.1-9.9) 10%
● Death 2.8%
● MI 4.2%
● CVA 1.2%
MALE 6.1% (4.2-8.6) 17 (5.4%, 3.2-8.4) 9%
Amputation 2.2% (1.1-3.9) 5 (1.5%, 0.5-3.6%) 4%
CVA,Cerebrovascular accident;MACE,major adverse cardiovascular event;
MI, myocardial infarction; OPG, objective performance goals.growing world-wide burden of CLI in a highly vulnerablepopulation with advanced cardiovascular disease. Surgical
bypass with autogenous vein remains the gold standard of
revascularization for patients who are suitable candidates.
The patient and limb-level outcomes for CLI are highly
dependent on baseline risk factor distribution, which ren-
ders meaningful comparisons of non-randomized data
prone to error due to mismatched populations. Risk strat-
ification is paramount for data reporting and for appropri-
Table VIIb. Summary of efficacy outcomes (one year)
for anatomic high risk (infra-popliteal) subgroup and
suggested OPG
Outcome Point (95% CI) Efficacy OPG
MALEPOD 74.0% (70.2-78.1) 67%
AFS 74.4% (70.6-78.3) 68%
RAS 44.0% (38.8-49.8) 36%
RAO 58.3% (54.0-63.0) 51%
Limb salvage 86.6% (83.6-89.8) 81%
Survival 85.9% (82.9-89.0) 80%
AFS, Amputation-free survival; CI, confidence interval; MALE, major ad-
verse limb event; OPG, objective performance goals; POD, perioperative
death; RAO, any reintervention or above ankle amputation of the index
limb;RAS, any reintervention, above ankle amputation of the index limb, or
stenosis.
Rates reported as proportion free from adverse event.
Table VIIIa. Summary of safety outcomes for conduit
high risk (non-SSGSV or diameter  3 mm) subgroup
Outcome
30 day events
(%; 95% CI)
Maximum allowable
events (Trial N  333)
Safety
OPG
MACE 6.1% (3.0-11.0) 25 (7.5%, 4.9-10.9) 11%
● Death 1.8%
● MI 4.3%
● CVA 1.2%
MALE 9.2% (5.2-14.7) 36 (10.8%, 7.7-14.7) 15%
Amputation 3.1% (1.0-7.0) 14 (4.2%, 2.3-7.0) 7%
CVA,Cerebrovascular accident;MACE,major adverse cardiovascular event;
MI, myocardial infarction; OPG, objective performance goals.
Table VIIIb. Summary of efficacy outcomes (one year)
for conduit high risk (non-SSGSV or diameter  3 mm)
subgroup and suggested OPG
Outcome Point (95% CI) Efficacy OPG
MALEPOD 69.2% (62.3-76.9) 62%
AFS 76.4% (70.1-83.2) 70%
RAS 30.0% (23.1-39.1) 23%
RAO 46.3% (38.9-55.1) 39%
Limb salvage 87.5% (82.3-92.9) 82%
Survival 86.3% (81.2-91.8) 81%
AFS, Amputation-free survival; CI, confidence interval; MALE, major ad-
verse limb event; OPG, objective performance goals; POD, perioperative
death; RAO, any reintervention or above ankle amputation of the index
limb;RAS, any reintervention, above ankle amputation of the index limb, or
stenosis; SSGSV, single segment of great saphenous vein.
Rates reported as proportion free from adverse event.ate design of clinical trials in CLI.
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What is the optimal control group for comparing the
outcomes of a new catheter-based therapy in CLI? For
patients considered suitable for attempted open bypass, the
primacy of vein grafting seems well established in the
literature, though this concept has recently been chal-
lenged. The BASIL trial11 randomized patients to a bypass-
first versus angioplasty-first strategy, and demonstrated no
meaningful clinical difference within the first year, although
improved outcomes for surgery-first were evident at two
years and beyond.10 However, it is important to remember
that the design of this trial meant patients could only be
randomized if they were considered equally suitable (‘grey
area of clinical equipoise’) for both bypass surgery and
balloon angioplasty. In addition, prosthetic grafts com-
prised more than 25% of the bypasses in the surgery-first
arm, and only a small number of the interventions per-
formed were at the infrapopliteal level. Balloon angioplasty
(PTA) must still be considered a relatively unproven ther-
apy for CLI, and currently there is inadequate data (both
quantity and quality) to base an OPG for CLI on PTA
outcomes. Patients deemed unsuitable for surgical revascu-
larization may be ideal candidates for endovascular ap-
proaches; however, data available from pharmacologic and
gene therapy trials are limited, and are highly skewed by the
extensive selection criteria employed. Conversely, the mul-
ticenter datasets available for open bypass surgery in CLI
provided a rich source of validated outcomes for generating
OPG. These data provide the most suitable current frame-
work for non-randomized comparisons. An RCT approach
would be required to directly compare new device technol-
ogy with PTA alone, or with best medical therapy in
non-operative candidates.
Important limitations
There were few available RCT in the CLI population
that could serve as potential sources for this analysis. These
trials had limited data in regard to some variables that may
have significant impact on outcomes, most especially de-
gree of tissue loss and anatomic extent of disease. In addi-
tion to the limitations imposed by patient selection, the use
of an open surgery control group did not allow for bench-
marking of important adverse events that may be unique to
catheter-based therapies. In the same way that wound
dehiscence is a uniquely surgical complication, access-
related complications (eg, pseudoaneurysm, arteriovenous
Table IX. Mean reinterventions per limb-year
Overall
Mean reinterventions
Low risk High risk
Reintervention count 0.64
Clinical 0.66 0.53
Anatomical 0.66 0.62
Conduit 0.49 0.91fistula) for catheter-based approaches cannot be comparedwith bypass controls, but must be reported in device trials.
Most concerning among these is the potential risk of plaque
embolization with loss of run-off vessels or additional tissue
injury, a complication reported with significant frequency
for endovascular procedures such as atherectomy,16,17 and
one that may severely impact patient outcomes. The surgi-
cal control data did not provide usable information on
clinical deterioration (ie, worsening of Rutherford grade).
We believe that clinical trials of catheter-based approaches
in CLI should report peri-procedural rates of embolization
and clinical deterioration, and suggest a framework for
defining such endpoints in the Appendix (online only).
We defined a risk stratification scheme based on
clinical, anatomic, and conduit availability criteria that
were supported by statistical analysis and were felt to be
practical for clinical trial execution. We provided specific
OPG for defined high-risk cohorts, and others (eg, end-
stage renal disease) could be considered with more data.
The potential advantages of catheter-based therapies
would seem most attractive in a high risk setting. Al-
though not provided in this manuscript, OPG for the
complementary low-risk groups (ie, for trials excluding
these defined high-risk patients) could be generated
from the existing data. It is noteworthy that diabetes was
not associated with differential mortality or AFS in the
surgical bypass controls, and had a marginal impact on
the primary efficacy endpoint.
It should be stressed that these data were compiled
from surgical RCTs with broadly inclusive entry criteria,
most importantly in regard to tissue loss. The percentage
of tissue loss patients was 69%-75% across the three trials
and Rutherford 6 category patients were included in all.
As tissue loss is one of the more potent variables influ-
encing outcomes in the CLI population, single-arm
studies based on these OPG must enroll a similar popu-
lation to be comparable to these data. Specifically, stud-
ies in which Rutherford 6 patients are either excluded or
not represented in enrollment can not be compared with
the outcomes from these surgical controls. With further
data collection from ongoing or future trials, it may be
possible to provide additional risk-stratified OPG based
on the prevalence and severity of tissue loss in a given
CLI cohort.
Efficacy measures in CLI and non-inferiority
No single efficacy endpoint captures the full impact of
revascularization in CLI, and we have pointed out the
hazards of non-randomized comparisons for endpoints
such as AFS or limb salvage, whichmay be highly skewed by
patient selection. Efficacy of revascularization must be as-
sessed at both limb and patient levels, and is incompletely
measured by clinical events such as amputation or reinter-
vention. All survival-based outcomes incorporate only the
first clinical event, and therefore do not assess the cumula-
tive burden of multiple procedures or symptom recurrences
on the patient. The timing of such events is heavily influ-
enced by clinical judgment of the treating physician. Re-
porting of the frequency and magnitude of all subsequent
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treatments that are fraught by limited durability. We have
recognized the difference between minor and major rein-
terventions in definition of the primary efficacy endpoint.
Finally, there are challenges evident in attempting to com-
pare hemodynamic success between open surgery and en-
dovascular therapies, primarily related to established sur-
veillance methodologies on the one hand and a lack thereof
in the other. Future trials should incorporate measures of
sustained hemodynamic benefit, since this is an objective
endpoint directly linked to the efficacy of revascularization.
A majority, though not all, of CLI patients meeting the
defined entry criteria will experience recrudescence of isch-
emic symptoms in the limb upon treatment failure, though
the timing and severity of presentation may be highly
variable. We have suggested a definition for hemodynamic
success in CLI (Appendix, online only) and have used
the reintervention/amputation/stenosis endpoint from
the open surgery data to define an OPG. We recognize the
measures are slightly different in derivation, but are suffi-
ciently comparable in our view to justify this approach at
this time. Duplex ultrasound is a highly sensitive and vali-
dated measure for vein graft disease, and the resulting rate
of reintervention and stenosis in the surgical trials are
reflected by the lowOPG target of 39%. Further refinement
of a hemodynamic performance goal for catheter-based
therapies in CLI may be attainable with data from future
trials utilizing the assessment and reporting standards sug-
gested herein. Other important clinical outcomes in CLI
such as wound healing, relief of pain, and level of function
suffer from lack of standardization of measures and unavail-
able or incomplete data.
The definition of non-inferiority for a less invasive
treatment strategy is to some degree subjective, and the
recommendations provided herein reflect the consensus of
the Working Group. In assessing safety measures, we ratio-
nalized that outcomes for open surgery should be the upper
limit of acceptability for major peri-procedural events.
Comparison to a standard PTA group might be more
relevant for assessing safety of catheter-based devices; un-
fortunately, adequate data for the CLI population do not
exist. For efficacy, we attempted to strike a balance between
reduced invasiveness and durability versus masking poten-
tial futility of the test therapy in the absence of randomized
controls. Sample size requirements were modeled across a
range of non-inferiority margins (0%-5%) for the key effi-
cacy endpoints. We selected an additional 3% buffer in
setting the efficacy OPGs, which amounted to a 5%-23%
relative increase in allowable event rates in comparison to
the open controls. Reducing or eliminating the non-
inferiority margin from the all-comers or anatomic high risk
cohorts would result in a dramatic increase in the required
sample sizes for a single-arm trial, likely rendering the OPG
impractical for use.
Comparison to available endovascular data
Comparison of these suggested OPG to published
reports of endovascular treatment of CLI is challenging dueto small patient numbers, differences in patient selection,
use of multiple therapeutic modalities, variable or inconsis-
tent endpoints, lack of confidence intervals for data, and
variable study duration. The LACI (Laser Angioplasty for
Critical Limb Ischemia) trial18 enrolled 145 patients with
155 critically ischemic limbs, 69% of whom presented with
tissue loss. Technical success rates were low (85%), and
adjunctive stent placement was utilized in 45%. At six
months, they reported an amputation-free survival (AFS)
point estimate of 82%. Direct comparison to the one-year
suggested AFS OPG of 71% is not possible. Bosiers et al
presented a series of 51 critically ischemic limbs in 47
patients treated with angioplasty and nitinol (XPert) stents
for infrapopliteal disease.19 The protocol allowed only one
or two stents to be deployed, resulting in a mean lesion
length of 32.4 mm, and also permitted intervention on a
diseased tibial artery in the presence of a second patent
tibial artery. The one-year AFS for this cohort was 79%,
suggesting that the lower confidence level might fall within
the suggested AFS OPG of 68% for high-risk anatomy.
However, clinicians should remain cautious of extrapolat-
ing these results to the treatment of diffuse tibial disease.
Giles20 reported a retrospective series of 163 patients (176
limbs) who underwent infrapopliteal angioplasty for CLI.
At one year, the incidence of restenosis, major amputation,
or reintervention for the treated limbs was 39% (no confi-
dence interval [CI] reported), comparable to the suggested
OPG of 36% for infrapopliteal anatomy. Lastly, we com-
pared outcomes of the BASIL Trial10 angioplasty arm with
the proposed OPGs. For the primary efficacy endpoint,
perioperative death or any major adverse limb event in the
BASIL angioplasty arm was 68.6% (95% CI, 62.6%-75.1%),
failing to meet the OPG of 71%. It is noteworthy, however,
that the BASIL results would meet the primary endpoint
OPG of 62% for a high-risk conduit subgroup. In summary,
comparison of the proposed OPGs to current literature is
statistically challenging. However, the latter two examples
show that recent angioplasty results may approach or ex-
ceed the proposed OPG for selected populations, confirm-
ing that the proposed standards are challenging but not
insurmountable. Furthermore, new devices for CLI should
be expected to outperform standard angioplasty if they are
to become a useful and cost-effective clinical tool.
Regulatory environment for CLI and appropriate role
for OPGs
Off-label use of devices in the treatment of peripheral
atherosclerosis is currently extensive, and is a by-product of
the existing regulatory framework. In many cases, device
application is driven by available sizes, sheath, and guide-
wire considerations, as opposed to demonstrated safety and
efficacy for the clinical condition being treated. A compli-
cating feature is that a given catheter-based device may not
be applied, or effective, as a stand-alone therapy. However,
we believe that new devices clearly targeting the CLI pop-
ulation should be required to demonstrate specific efficacy
in that disease. This should be considered to include any
device intended to treat occlusive lesions in the infrapopli-
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appropriate clinical indication. Devices seeking approval for
use in the superficial femoral artery (SFA) should be limited
to appropriate sizes for that vessel, and their extension to
smaller, more distal vessels be regulated within the CLI
framework suggested. Similarly, safety and efficacy consid-
erations for the coronary circulation are entirely different
from those in the periphery.
It is important to reiterate the contrast between these
suggested OPG and the development of evidence-based
guidelines for clinical practice. OPG are designed to pro-
vide a framework for determining appropriate entry of a
candidate therapy into the market, meeting the least-
burdensome criteria by which FDA regulates medical de-
vices. The optimal role for such therapies in patient care
must be based on subsequent clinical investigation. The
best evidence to support clinical practice comes from well-
executed and adequately powered RCTs, which are sorely
lacking in the CLI arena. Such RCTs should employ two
years as the minimal observation time for clinical outcomes,
and should incorporate the guidelines for cohort definition,
risk stratification, endpoint assessments, and outcomes
measures suggested herein.
As additional data become available for endovascular
treatments in CLI, these OPG are expected to require
periodic reassessment and updating. Prospectively col-
lected, validated data employing a uniform approach to
cohort definition, surveillance, and endpoint definitions in
CLI are sorely needed. The suggestions set forth in this
manuscript and the Appendix (online only) provide such a
framework.
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clinical trial design in CLI
A. Inclusion/Exclusion Criteria
CLI is defined as ischemic rest pain or tissue loss,
consistent with Fontaine Stages III-IV and Rutherford
Classes 4-6. Documentation of severely compromised he-
modynamics (ankle 50 mm Hg, toe 30 mm Hg,
TcPO230 mmHg) should be used to verify inclusion of
patients with rest pain. For minor tissue loss (Rutherford
5), ankle and toe pressures should be less than 70 mm Hg
and 50 mmHg, respectively. For patients with more exten-
sive tissue loss, either documentation of severely compro-
mised hemodynamics or confirmed absence of pedal pulses
should be required.
Patients with acute limb-threatening ischemia, trauma,
non-atherosclerotic disease (eg, arteritis), embolic disease,
or documented hypercoagulable states should be excluded.
Patients with end-stage renal disease (CKD 5) and CLI
have markedly inferior survival and limb-related out-
comes—therefore they should either be excluded from an
all-comers trial or subject to stratification in the design.
There is insufficient data upon which to base an OPG for
the end-stage renal population.
B. Risk factor profile
Baseline demographic, comorbidity, and anatomic
variables have profound influence on patient mortality,
complications, and successful revascularization. All CLI
studies should collect and report data on the following key
factors:
● Demographic - age, gender, race/ethnicity
● Disease severity - Rutherford stage, ankle pressure/toe
pressure/ABI/TBI
● Comorbidities - coronary artery disease, diabetes mel-
litus (and type), hypertension, dyslipidemia, smoking
status, renal disease (CKD classification)
● Concomitant medications - antithrombotic, choles-
terol lowering, cardioprotective medications
● Anatomic level of disease - femoropopliteal versus
infrapopliteal, TASC II classification
RCTs should demonstrate adequate balance between
arms for these key variables. Non-randomized studies
should consider a priori stratification or report data for the
following specific subgroups:
● Clinical high risk- age  80, presence of tissue loss
● Anatomic high-risk- infrapopliteal arterial occlusive
disease
Vein quality is a primary determinant of the outcome of
surgical revascularization. Therefore, patients lacking ade-
quate saphenous vein are a bona fide subgroup for a test
therapy, as demonstrated by the data provided in this
manuscript. Definition of such a cohort for exclusive or
stratified trial design should incorporate duplex ultrasound
vein mapping of both lower extremities. Criteria to estab-
lish the conduit high-risk cohort include inadequate lengthof saphenous vein of sufficient quality (3 mm diameter,
normal compressibility, absence of morphologic changes
suggestive of sclerosis) to construct the planned revascular-
ization. Patients lacking ipsilateral saphenous vein in whom
the contralateral extremity is also afflicted by severe periph-
eral artery disease (Rutherford categories 3-6, ABI 0.5)
may be considered for this category if clinical judgment
precludes use of the contralateral intact saphenous vein.
C. Suggested assessments
Follow-up surveillance should be included in any clin-
ical trial evaluating peripheral revascularization. Clinical
follow-up routinely includes documentation of pulses, as-
sessment of wounds and healing, evidence of change in
symptoms. Noninvasive hemodynamic assessment of the
treated limb is essential. Methods of noninvasive assess-
ment include:
● ABI - defined as the highest ankle pressure divided by
the highest brachial pressure. If ankle signal is non-
compressible or if pressures greater than 250 mm Hg
(or ABI 1.3), then absolute toe pressure/TBI
should be performed21
● Duplex ultrasound (DUS) - this is a standardmeans for
assessment of vein bypass grafts. For endovascular
procedures, ultrasound criteria should be used if re-
porting patency/restenosis of specific treated arterial
segments;22 however, global limb hemodynamics
(ABI or TBI) are more relevant to the patient’s clinical
status and are simpler to collect reproducibly across
centers in a large trial. Because duplex ultrasound
criteria are more sensitive than ABI for the diagnosis of
hemodynamic failure in vein grafts, ultrasound find-
ings supersede ABI for defining restenosis in open
surgical reconstruction.
The following is suggested as a minimum schedule of
vascular assessments in a CLI intervention trial:
● Baseline (pre-intervention) - ABI or toe pressure.
● Post-procedure (immediately or up to one week after)
- ABI or toe pressure
● One, three, six, 12 months - ABI or toe pressure for all
endovascular interventions. DUS for all bypass cases.
DUS arterial examination suggested for assessment of
specific endovascular-treated segments
● Angiography (catheter-based, magnetic resonance, or
computed tomography techniques) should be per-
formed as clinically indicated by the presence of recur-
rent symptoms or if results of noninvasive studies
suggest hemodynamic failure.
Functional and quality of life (QoL) outcomes such as
ambulatory status, independent living status, and pain
should also be assessed at baseline and during follow-up.
There is no gold standard instrument for QoL measure-
ment in the CLI population; the Short Form-36 (SF-36),
EuroQol, and VascuQol have been used for this purpose.
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We suggest a definition of hemodynamic failure as an
endpoint in future CLI trials, reported in a time-to-event
fashion as the first occurrence of any of the following
events:
● Major amputation (transtibial or above)
● Reintervention to maintain vascular patency in the
index limb
● Failure to increase ABI by at least 0.15 post-procedure
as compared with baseline value. For patients with
non-compressible vessels, toe-brachial index (TBI)
should increase by at least 0.10
● Decrease in ABI by 0.15 (or TBI drop of 0.10) or
greater as compared with post-procedure value
● Duplex ultrasound demonstrating occlusion of the
graft or treated native vessel
● Duplex ultrasound demonstrating critical graft steno-
sis (PSV 300 cm/sec or velocity ratio  3.0)
● Angiogram demonstrating occlusion of graft or of any
treated vessel, or greater than 50% stenosis in the
presence of recurrent clinical symptoms
E. Endpoints and reporting
Peri-procedural complications including death, MACE,
amputation, and reinterventions should be reported. Stan-
dard surgical complications include bleeding, wound-re-
lated morbidity, and reoperations. For catheter-based
treatments, access site complications, contrast-induced
complications, and evidence of embolization should be
reported as key safety outcomes. Embolization events
should be classified as either major (loss of a major named
branch of the femoral, popliteal, tibial, or pedal vessels; or
change in clinical status), or minor (loss of unnamed
branches or clinical evidence of diffuse microemboli [ie,
“trash foot”]). While improvement in ischemic signs/
symptoms may be variable following successful revascular-
ization, clear evidence of deterioration (ie, decline in Ruth-
erford grade from baseline) should be reported.
Follow-up in CLI trials should be for a minimum of
one-year, and two years would be preferred based on theresults of recent studies. Efficacy measures should include
standard endpoints such as death, major amputation, and
graft patency. They should also include the following mea-
sures:
● Reinterventions: classified as major/minor, first occur-
rence, and total number over time in the index limb
Œ Major reinterventions include placement of a new
surgical bypass graft, use of thrombectomy or
thrombolysis, or a major surgical revision (jump or
interposition graft)
Œ Minor reinterventions include endovascular proce-
dures without thrombectomy/thrombolysis and
minor surgical revisions (patch angioplasty)
● Major Adverse Limb Event: composite of either am-
putation or major reintervention
● Hemodynamic failure: as defined above
● Clinical failure: worsening or recrudescence of symp-
toms, decline in Rutherford grade.
Endpoints reported should include perioperative death
plus any major adverse limb event, AFS, reintervention/
amputation, hemodynamic failure, sustained clinical suc-
cess (freedom from clinical failure). See manuscript text for
definitions.
F. Wound healing
Patients with CLI and non-healing wounds incur pain,
disability, and extensive treatments that may be dramati-
cally relieved by effective revascularization. Wound healing
is an important measure of clinical success, but is fraught
with difficulties as a clinical trial endpoint. Wound care
guidelines should be established by protocol to provide
uniform care for all subjects in a trial where healing is an
endpoint. Ulcers should be photographed at baseline, at
three months, six months, and 12 months post-treatment,
and prior to revascularization or major amputation. The
size of ischemic ulcers at baseline should be reviewed by
independent core laboratory and the complete healing of
the target ulcers post-treatment should also be confirmed
by an independent observer (physician). The duration of
complete healing as confirmed by the outside observer
should be at least two weeks.
surgery controls, N  605.
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freedom from perioperative death or any Major Adverse Limb
Event (MALEPOD), open surgery controls, full dataset N 
838.Fig 5 (online only). K-M plot for the key secondary endpoint,
amputation-free survival (AFS), open surgery controls, full dataset
N  838.Fig 6 (online only). K-M plot for the secondary endpoint of
freedom from reintervention or amputation (RAO), open surgery
controls, full dataset N  838.Fig 7 (online only). K-M plot for the secondary endpoint of
freedom from reintervention, amputation or stenosis (RAS), open
